Hellenic News of America reports that LIMR President George Prendergast, PhD, says Lankenau was an ideal location for the annual meeting because of its early work in immunochemotherapy. More than a decade ago, LIMR researchers uncovered IDO1 inhibitors, drugs that disrupt the process by which tumors evade a patient’s immune system.
The Lankenau Institute for Medical Research hosts the 4th International Conference on Immunochemotherapy
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.